Payment overview · 2025
General Payments
$248.02
12 reported records · 9 companies
Healthcare provider profile · identity verified
Rachael E Sapp, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MADISON, FL · NPI 1730127044
Verified facts
What the public records show
CMS Open Payments records show Rachael E Sapp, ARNP received $248.02 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 487 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.83 | 20.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.83 | 14.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.16 | 14.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.80 | 11.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.82 | 9.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.13 | 8.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.84 | 8.4% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $18.14 | 7.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.47 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $248.02 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.83 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.83 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.83 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 98 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 78 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 98 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
98 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
98 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
241 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
78 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
90 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
487 | 81 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1010 | 167 |
| Atorvastatin Calcium | Atorvastatin Calcium | 809 | 174 |
| Trazodone Hcl | Trazodone Hcl | 778 | 132 |
| Furosemide | Furosemide | 701 | 139 |
| Losartan Potassium | Losartan Potassium | 690 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 676 | 162 |
| Gabapentin | Gabapentin | 537 | 127 |
| Potassium Chloride | Potassium Chloride | 511 | 95 |
| Eliquis | Apixaban | 487 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 436 | 108 |
| Tramadol Hcl | Tramadol Hcl | 390 | 97 |
| Omeprazole | Omeprazole | 389 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 376 | 82 |
| Lisinopril | Lisinopril | 348 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 324 | 90 |
| Prednisone | Prednisone | 314 | 167 |
| Metoprolol Tartrate | Metoprolol Tartrate | 313 | 66 |
| Sertraline Hcl | Sertraline Hcl | 271 | 53 |
| Allopurinol | Allopurinol | 268 | 53 |
| Jardiance | Empagliflozin | 241 | 39 |
| Doxazosin Mesylate | Doxazosin Mesylate | 223 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 218 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 51 |
| Hydralazine Hcl | Hydralazine Hcl | 210 | 46 |
| Levofloxacin | Levofloxacin | 203 | 91 |
| Buspirone Hcl | Buspirone Hcl | 200 | 43 |
| Montelukast Sodium | Montelukast Sodium | 198 | 50 |
| Pregabalin | Pregabalin | 198 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 193 | 36 |
| Metformin Hcl Er | Metformin Hcl | 181 | 44 |
| Glipizide Er | Glipizide | 165 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 164 | 37 |
| Glipizide | Glipizide | 162 | 26 |
| Famotidine | Famotidine | 154 | 37 |
| Carvedilol | Carvedilol | 151 | 36 |
| Clonidine | Clonidine | 148 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 50 |
| Donepezil Hcl | Donepezil Hcl | 133 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 131 | 37 |
| Azithromycin | Azithromycin | 127 | 88 |
| Fluconazole | Fluconazole | 126 | 56 |
| Metformin Hcl | Metformin Hcl | 126 | 39 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 125 | 27 |
| Finasteride | Finasteride | 122 | 19 |
| Levetiracetam | Levetiracetam | 121 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 116 | 58 |
| Baclofen | Baclofen | 115 | 24 |
| Meloxicam | Meloxicam | 115 | 37 |
| Ezetimibe | Ezetimibe | 113 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 28 |
| Lorazepam | Lorazepam | 109 | 25 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 108 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 108 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 102 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 35 |
| Farxiga | Dapagliflozin Propanediol | 98 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 98 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 97 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 95 | 32 |
| Midodrine Hcl | Midodrine Hcl | 92 | 14 |
| Lactulose | Lactulose | 91 | 32 |
| Entresto | Sacubitril/Valsartan | 90 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 90 | 44 |
| Mirtazapine | Mirtazapine | 87 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 11 |
| Fenofibrate | Fenofibrate | 85 | 19 |
| Megestrol Acetate | Megestrol Acetate | 85 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 85 | 38 |
| Celecoxib | Celecoxib | 84 | 22 |
| Amoxicillin | Amoxicillin | 83 | 56 |
| Metoclopramide Hcl | Metoclopramide Hcl | 81 | 24 |
| Bumetanide | Bumetanide | 80 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 78 | 32 |
| Mounjaro | Tirzepatide | 78 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 25 |
| Nystatin | Nystatin | 75 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 16 |
| Alprazolam | Alprazolam | 73 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 16 |
| Clonidine Hcl | Clonidine Hcl | 69 | 24 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 69 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 68 | 21 |
| Ozempic | Semaglutide | 68 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 22 |
| Methocarbamol | Methocarbamol | 65 | 25 |
| Methimazole | Methimazole | 64 | suppressed |
| Xarelto | Rivaroxaban | 63 | 11 |
| Spironolactone | Spironolactone | 62 | 16 |
| Ibuprofen | Ibuprofen | 60 | 23 |
| Rybelsus | Semaglutide | 60 | suppressed |
| Lamotrigine | Lamotrigine | 59 | suppressed |
| Simvastatin | Simvastatin | 58 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Memantine Hcl | Memantine Hcl | 55 | 15 |
| Metolazone | Metolazone | 54 | 16 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 53 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 51 | 16 |
| Risperidone | Risperidone | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 49 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Clonazepam | Clonazepam | 48 | 12 |
| Primidone | Primidone | 47 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Nifedipine Er | Nifedipine | 46 | 14 |
| Ondansetron Odt | Ondansetron | 44 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 16 |
| Atenolol | Atenolol | 42 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 13 |
| Topiramate | Topiramate | 40 | 11 |
| Valsartan | Valsartan | 40 | 12 |
| Trulicity | Dulaglutide | 38 | 12 |
| Hydrocortisone | Hydrocortisone | 37 | 19 |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 21 |
| Santyl | Collagenase Clostridium Hist. | 33 | suppressed |
| Anastrozole | Anastrozole | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 14 |
| Lithium Carbonate | Lithium Carbonate | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | 19 |
| Klor-Con 10 | Potassium Chloride | 29 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 18 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 27 | 23 |
| Novolin N | Insulin Nph Human Isophane | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 25 | suppressed |
| Repaglinide | Repaglinide | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Erythromycin | Erythromycin Base | 23 | 14 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 13 |
| Novolog | Insulin Aspart | 21 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | 14 |
| Haloperidol Lactate | Haloperidol Lactate | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Paliperidone Er | Paliperidone | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 17 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Fycompa | Perampanel | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $248.02 · 12 records | ABBVIE INC. | Auvelity, BREZTRI, FARXIGA, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, TRELEGY ELLIPTA, VRAYLAR, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error